An open label study to assess the safety and effect on disease activity of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to prior treatment with DMARDs and/or one anti-TNF alpha agent.
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- 31 Aug 2018 Biomarkers information updated
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2012 Actual patient number changed from 196 to 215 as reported by ClinicalTrials.gov.